Former Chief Commercial Officer · EAGLE PHARMACEUTICALS, INC. (EGRX)

Michael Moran

A named executive officer of EAGLE PHARMACEUTICALS in every fiscal year CompBrief holds from FY2021 to FY2022. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2022

$2,608,325

Salary $277,692Stock awards $2,310,029

FY2021: $1,857,933

2nd of 3 named executive officers at Eagle Pharmaceuticals by FY2022 total.

3 named officers on file for EAGLE PHARMACEUTICALS, FY2022

Michael Moran’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 5 equity grants, each cited to its filing
  • EGRX’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how EAGLE PHARMACEUTICALS’s whole pay program stands against its peers

  • EAGLE PHARMACEUTICALS’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on EGRX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed May 1, 2023 (DEF 14A).

Free

Get Michael Moran’s full pay file as a PDF — free

More than this page: up to 10 years of Michael’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Michael Moran compensation by year

EAGLE PHARMACEUTICALS Summary Compensation Table · all 2 fiscal years held
In US dollars, as EAGLE PHARMACEUTICALS reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022
Salary$424,296$277,692
Bonus$0$0
Stock awards$987,362$2,310,029
Option awards$0$0
Non-equity incentive$418,540$0
Pension and deferred compensation$0$0
All other$27,735$20,604
Total$1,857,933$2,608,325

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: EAGLE PHARMACEUTICALS, INC. DEF 14A filed May 1, 2023, accession 0001104659-23-054338, and prior-year filings. Open the filing on EDGAR.

How this page was built: the EAGLE PHARMACEUTICALS, INC. filed document, accession 0001104659-23-054338. Every figure is read from that document and cited to the page and table it appears in. Filed May 1, 2023.

$1.9M
$2.6M
FY21
FY22
SalaryNon-equity incentiveStock awardsAll other

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU11,250$572,850—
RSU8,200$417,544—
PSU8,200$417,544—
PSU7,100$361,532—
RSU1,125$57,285—
Option1,219—$41.37
Option104—$59.14
Option19,531—$59.79

Per the Outstanding Equity Awards at Fiscal Year-End table in EAGLE PHARMACEUTICALS, INC.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Change-in-control & termination

estimated payments EAGLE PHARMACEUTICALS discloses, by trigger · FY2022
TriggerCash severanceAccelerated equityBenefits continuationTotal as disclosed
Involuntary termination without cause$0$0$0$0

Per the Potential Payments Upon Termination or Change in Control table in EAGLE PHARMACEUTICALS, INC.'s FY2022 proxy. Estimates as the company printed them; a dash means it printed no figure.

EAGLE PHARMACEUTICALS’s named executive officers, FY2022

as the company reported each
Named executive officerRoleFY2022 total
Scott TarriffPresident, Chief Executive Officer, Director$10,520,577
Michael Moran · this pageFormer Chief Commercial Officer$2,608,325
Brian CahillChief Financial Officer$2,493,347

The full EAGLE PHARMACEUTICALS compensation record

free company brief

This page is one person within EAGLE PHARMACEUTICALS's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the EAGLE PHARMACEUTICALS proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are EAGLE PHARMACEUTICALS's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Michael Moran's compensation dossier · One-time report. No refunds.